PIPELINE A broad pipeline of unique, world-class candidates with the potential to revolutionize the prevention and treatment of cancer and infectious disease. Our AI-technology enables a high level of scalability, offering the potential to expand our portfolio and our proprietary platforms to the benefit of patients worldwide.

EVX-01 is a peptide-based neoantigen cancer therapy intended for the first-line treatment of a variety of metastatic and unresectable melanoma. Whilst checkpoint inhibitors have revolutionized the treatment of melanoma, too many patients still die from this cancer. EVX-01 has shown promising clinical results in, with patients benefitting - and even recovering - after receiving the therapy. Evaxion is now conducting a large phase 2 clinical trial with this candidate.